Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc.

Biotechnology • Healthcare • San Diego, CA, United States • AARD (NMS)

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

858 225 7696 4370 La Jolla Village Drive, San Diego, CA 92122, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

William Blair Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform Recommendation - Nasdaq
Nasdaq • Dec 12
Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy - Investing.com
Investing.com • Dec 11
Aardvark Therapeutics prices $94M IPO at $16 per share - MSN
MSN • Dec 29
Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment - Yahoo Finance
Yahoo Finance • Oct 17
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
MarketBeat • Dec 22

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Aardvark Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Aardvark Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Aardvark Therapeutics, Inc. have?
Aardvark Therapeutics, Inc. has approximately 33 employees.
What industry is Aardvark Therapeutics, Inc. in?
Aardvark Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Aardvark Therapeutics, Inc. a publicly traded company?
Yes, Aardvark Therapeutics, Inc. is publicly traded under the ticker symbol AARD on the NMS. The company has a market capitalization of approximately $0.30 billion.
Where is Aardvark Therapeutics, Inc. headquartered?
Aardvark Therapeutics, Inc. is headquartered in San Diego, CA, United States at 4370 La Jolla Village Drive, San Diego, CA 92122, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.